Quick Takeaways
- ANTARES PHARMA, INC. has 11 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 11 Insiders of ANTARES PHARMA, INC.
- Location
- Ewing, NJ
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
ANTARES PHARMA, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Thomas J. Garrity | Director | Mixed | 24 May 2022 | |||
| Anton Gueth | Director | Mixed | 24 May 2022 | |||
| Robert F. Apple | President and CEO, Director | Mixed | 24 May 2022 | |||
| Peter J. Graham | EVP, General Counsel, Chief Compliance Officer and Secretary | Mixed | 24 May 2022 | |||
| Fred M. Powell | Executive Vice President & CFO | Mixed | 24 May 2022 | |||
| Leonard S. Jacob | Director | Mixed | 24 May 2022 | |||
| Peter C. Richardson | EVP, Research and Development and Chief Medical Officer | Mixed | 24 May 2022 | |||
| Robert P. Roche Jr. | Director | Mixed | 24 May 2022 | |||
| Karen L. Smith | Director | Mixed | 24 May 2022 | |||
| Peter Greenleaf | Director | Mixed | 24 May 2022 | |||
| Carmen B. Volkart | Director | Mixed | 24 May 2022 |
Top shareholders of ANTARES PHARMA, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Recent Insider Transactions by Companies or Individuals for ANTARES PHARMA, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.